Generation and in vitro functional characterization of anti-CD22 chimeric antigen receptor T cells derived from newly generated monoclonal antibody clones
7 affiliations
- 1Faculty of Pharmaceutical Science, MSc Program in Research for Enterprise, Chulalongkorn University, Bangkok, Thailand
- 2Center of Excellence in Cellular Immunotherapy, Chulalongkorn University, Bangkok, Thailand
- 3Cell and Gene Therapy Manufacturing Center, King Chulalongkorn Memorial Hospital, Bangkok, Thailand
- 4Faculty of Medicine, Center of Excellence in Systems Biology, Chulalongkorn University, Bangkok, Thailand
- 5Thailand Hub of Talents in Cancer Immunotherapy, Bangkok, Thailand
- 6Department of Pharmacology and Physiology, Faculty of Pharmaceutical Sciences, Chulalongkorn University, Bangkok, Thailand
- 7Department of Research Affairs, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand
Abstract
Chimeric antigen receptor (CAR) T-cell therapy has transformed the treatment of B-cell malignancies, but relapse after CD19-directed therapy remains a major challenge, often because of loss or downregulation of CD19 expression. CD22 is an attractive alternative target because it is expressed on malignant B cells, including in many cases of CD19-negative disease. In this study, we generated and characterized novel anti-CD22 monoclonal antibody–derived CAR constructs for in vitro evaluation. Four anti-CD22 monoclonal antibody clones were initially screened, and two clones, 24A7G6 and 29H9C8, were selected for CAR development based on their favorable binding and CAR surface expression profiles. Second-generation CAR constructs containing either a 4−1BB or CD28 costimulatory domain were generated and introduced into primary human T cells. The resulting CAR T cells were evaluated for expansion, immunophenotype, activation and inhibitory marker expression, cytokine secretion, short-term cytotoxicity, long-term co-culture activity, and sequential tumor rechallenge against CD22-positive Raji and Nalm-6 cells and CD22-negative K562 cells. Both 24A7G6- and 29H9C8-derived CAR T cells expanded efficiently, showed predominant CD8 + populations with naïve and central memory phenotypes, and mediated potent antigen-specific cytotoxicity against CD22-positive target cells, while showing no activity against CD22-negative cells. Following antigen stimulation, CAR T cells upregulated activation markers and showed modest increases in inhibitory receptors. In long-term co-culture and sequential rechallenge assays, all constructs retained antitumor activity under prolonged antigen exposure. Notably, the 24A7G6-CD28 CAR demonstrated enhanced sustained tumor control compared with the corresponding 4−1BB construct in extended assays, whereas short-term cytotoxicity was broadly comparable across constructs. These findings show that the newly generated 24A7G6 and 29H9C8 scFvs can function as effective targeting domains for CD22-directed CAR T-cell development and provide an in vitro basis for prioritizing lead constructs for further preclinical evaluation.
Related
- Chimeric archaeal BHB-human pre-tRNA scaffold HARBOR system enables versatile production of functional circular RNA modalities
- Integrative discovery and functional dependency mapping uncover essential chimeric RNAs in the active transcriptome
- The generation and characterization of CTRP9-CreERT2 knock-in mice for targeting endothelial cell muscle and adipose tissues
- Generation and characterization of three human induced pluripotent stem cell lines from patients with Duchenne muscular dystrophy
- Strategies for Overcoming the Purification Challenges of Meis1 and HoxA9 and Their Functional Characterization
BibTeX
@article{ruengdej2026generation,
title = {{Generation and in vitro functional characterization of anti-CD22 chimeric antigen receptor T cells derived from newly generated monoclonal antibody clones}},
author = {Wipawadee Ruengdej and Vichaya Chuthaphakdikun and Sirirut Jewmoung and Nithidol Sakunrangsit and Chatikorn Boonkrai and Trairak Pisitkun and Supannikar Tawinwung and Koramit Suppipat},
journal = {PLOS One},
year = {2026},
month = nov,
doi = {10.1371/journal.pone.0362221},
url = {https://doi.org/10.1371/journal.pone.0362221},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Generation and in vitro functional characterization of anti-CD22 chimeric antigen receptor T cells derived from newly generated monoclonal antibody clones
AU - Wipawadee Ruengdej
AU - Vichaya Chuthaphakdikun
AU - Sirirut Jewmoung
AU - Nithidol Sakunrangsit
AU - Chatikorn Boonkrai
AU - Trairak Pisitkun
AU - Supannikar Tawinwung
AU - Koramit Suppipat
PY - 2026
DA - 2026/11/12
JO - PLOS One
DO - 10.1371/journal.pone.0362221
UR - https://doi.org/10.1371/journal.pone.0362221
AB - Chimeric antigen receptor (CAR) T-cell therapy has transformed the treatment of B-cell malignancies, but relapse after CD19-directed therapy remains a major challenge, often because of loss or downregulation of CD19 expression. CD22 is an attractive alternative target because it is expressed on malignant B cells, including in many cases of CD19-negative disease. In this study, we generated and characterized novel anti-CD22 monoclonal antibody–derived CAR constructs for in vitro evaluation. Four anti-CD22 monoclonal antibody clones were initially screened, and two clones, 24A7G6 and 29H9C8, were selected for CAR development based on their favorable binding and CAR surface expression profiles. Second-generation CAR constructs containing either a 4−1BB or CD28 costimulatory domain were generated and introduced into primary human T cells. The resulting CAR T cells were evaluated for expansion, immunophenotype, activation and inhibitory marker expression, cytokine secretion, short-term cytotoxicity, long-term co-culture activity, and sequential tumor rechallenge against CD22-positive Raji and Nalm-6 cells and CD22-negative K562 cells. Both 24A7G6- and 29H9C8-derived CAR T cells expanded efficiently, showed predominant CD8 + populations with naïve and central memory phenotypes, and mediated potent antigen-specific cytotoxicity against CD22-positive target cells, while showing no activity against CD22-negative cells. Following antigen stimulation, CAR T cells upregulated activation markers and showed modest increases in inhibitory receptors. In long-term co-culture and sequential rechallenge assays, all constructs retained antitumor activity under prolonged antigen exposure. Notably, the 24A7G6-CD28 CAR demonstrated enhanced sustained tumor control compared with the corresponding 4−1BB construct in extended assays, whereas short-term cytotoxicity was broadly comparable across constructs. These findings show that the newly generated 24A7G6 and 29H9C8 scFvs can function as effective targeting domains for CD22-directed CAR T-cell development and provide an in vitro basis for prioritizing lead constructs for further preclinical evaluation.
SN - 1932-6203
ER -